Israel Englander Summit Therapeutics Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Millennium Management LLC holds 30,000 shares of SMMT stock, worth $770,700. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,000

Previous 210,000 85.71%

Holding current value

$770,700

Previous $4.05 Million 84.25%

% of portfolio

0.0%

Previous 0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$16.64 - $36.7 $5.51 Million - $12.1 Million	-331,000 Reduced 37.32%	556,009 $11.8 Million
Q1 2025 May 15, 2025	SELL	$16.65 - $23.76 $19.4 Million - $27.6 Million	-1,162,820 Reduced 56.73%	887,009 $17.1 Million
Q4 2024 Feb 14, 2025	BUY	$17.52 - $23.46 $14.5 Million - $19.4 Million	827,483 Added 67.7%	2,049,829 $36.6 Million
Q3 2024 Nov 14, 2024	SELL	$6.89 - $31.93 $4.96 Million - $23 Million	-720,512 Reduced 37.09%	1,222,346 $26.8 Million
Q2 2024 Aug 14, 2024	BUY	$2.39 - $10.92 $4.64 Million - $21.2 Million	1,942,858 New	1,942,858 $15.2 Million
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.81 $1.04 Million - $2.21 Million	-787,210 Reduced 87.09%	116,723 $292,000
Q1 2023 May 15, 2023	BUY	$1.38 - $5.41 $1.25 Million - $4.89 Million	903,933 New	903,933 $1.58 Million
Q3 2022 Nov 14, 2022	SELL	$0.89 - $1.63 $23,058 - $42,230	-25,908 Reduced 5.66%	431,560 $514,000

Others Institutions Holding SMMT

# of Institutions

259

Shares Held

90.4M

Call Options Held

4.67M

Put Options Held

3.15M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $5.17B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account